TICKERNERD
Menu
CRSPCRSPHealthcare · Biotechnology

CRSP Stock Forecast: CRISPR Therapeutics AG Price Predictions for 2026-2027

Last close, 3 Aug 2026
$50
+3.29% on the day

The 23 Wall Street analysts covering CRISPR Therapeutics AG hold a median 12-month price target of $80 — +61.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$4.9B
Ticker Nerd rank
19 / 100
Median analyst target
$80
Analysts covering
23
Total return, dividends reinvested
1W
+6.1%
1M
−17.5%
YTD
−5.5%
1Y
−11.6%
From 52W high
−35.4%
From 52W low
+11.8%
$44
$77
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRSP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CRISPR Therapeutics AG on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
19 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
60
Volatility
50
Value
48
Quality
43
Momentum
41
Growth
35
Revisions
34
Size
25
Issuance
11

Accruals (60): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own CRISPR Therapeutics AG — and when they’d sell — is the membership.

Wall Street

CRSP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRSP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200$250$300Oct 25Jan 26Apr 26Jul 26CRSPHigh $291Median $80Low $44

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says23 analysts
14 Buy9 Hold0 Sell
Low $44Median $80High $291

The green dot is the last close — the median target sits +61.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 July 2026HC Wainwright & Co.ReiteratesBuy$80
6 July 2026CitizensReiteratesMarket Outperform$80
13 May 2026BernsteinMaintainsMarket Perform—
6 May 2026CitigroupMaintainsBuy—
17 Mar 2026Piper SandlerReiteratesOverweight—
17 Feb 2026Chardan CapitalMaintainsBuy—
13 Feb 2026Evercore ISI GroupMaintainsOutperform—
13 Feb 2026NeedhamMaintainsBuy—
13 Feb 2026TD CowenMaintainsHold—
30 Jan 2026CitizensMaintainsMarket Outperform—
23 Dec 2025CitizensReiteratesMarket Outperform—
23 Dec 2025NeedhamReiteratesBuy—
26 Nov 2025Chardan CapitalMaintainsBuy—
12 Nov 2025CitigroupMaintainsBuy—
11 Nov 2025BairdMaintainsNeutral—
11 Nov 2025RBC CapitalMaintainsSector Perform—
10 Nov 2025NeedhamMaintainsBuy—
17 Oct 2025B of A SecuritiesMaintainsBuy—
10 Oct 2025NeedhamReiteratesBuy—
23 Sept 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

CRSP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

CRISPR Therapeutics AG (CRSP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.7×

Cheaper than 91% of US stocks

Price / sales
1189.8×

Cheaper than 1% of US stocks

Price / book
2.6×

Cheaper than 37% of US stocks

EV / EBITDA
−5.6×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
68.6%

Higher than 91% of US stocks

Earnings growth (YoY)
—
Gross margin
−4494.9%

Higher than 1% of US stocks

Operating margin
−8933.3%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−31.2%

Higher than 26% of US stocks

Return on assets
−14.1%

Higher than 24% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CRSP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRSPCRISPR Therapeutics AG$4.9B
19
DYNDyne Therapeutics, Inc.$4.6B
27
CAICaris Life Sciences, Inc.$4.4B
30
TNGXTango Therapeutics, Inc.$4.4B
57
ACADACADIA Pharmaceuticals, Inc.$4.4B
65
MANEVeradermics, Inc.$4.3B
1
TVTXTravere Therapeutics, Inc.$5.0B
94
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRSP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest CRSP news & analysis

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 3 Aug 2026positive

CRISPR Therapeutics reported a Q2 loss of $0.94 per share, narrower than the Zacks Consensus Estimate of a $1.10 loss and an improvement from the $1.29 per share loss a year earlier. The company topped revenue estimates for the quarter.

Why it matters — The narrower-than-expected loss and revenue beat signal better-than-anticipated financial performance for the quarter, which CRSP watchers would track as a near-term results headline.

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 3 Aug 2026neutral

CRISPR Therapeutics announced it provided a business update and reported its financial results for the second quarter ended June 30, 2026. The announcement was made via GlobeNewsWire on August 3, 2026.

Why it matters — This quarterly financial report and business update represents the company's most recent disclosure of its operational and financial status, which CRSP watchers track to assess how the business is progressing.

CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider

Zacks Investment Research · 30 July 2026positive

CRSP closed at $48.44, up 1.68% from the prior session. The article notes the stock outperformed broader market returns.

Why it matters — The share-price move and the mention of exceeding market returns may be relevant to CRSP watchers tracking near-term performance.

FAQ

Frequently asked questions about CRSP stock

What is the CRSP stock price forecast for 2026-2027?

The 23 Wall Street analysts covering CRISPR Therapeutics AG have a median 12-month price target of $80, with estimates ranging from $44 to $291. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRSP stock a buy right now?

Of the 23 analysts covering CRISPR Therapeutics AG, 14 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CRISPR Therapeutics AG 19 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRSP?

As at 1 Aug 2026, CRISPR Therapeutics AG ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (60 of 100).

Will CRSP stock go up?

No one can know that. What the data says: the median 12-month target from 23 analysts implies +61.4% from the last close, and Ticker Nerd's factor model ranks CRISPR Therapeutics AG 19 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRSP stock forecast for 2030?

No analyst covering CRISPR Therapeutics AG publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRSP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $44 to $291 over the next 12 months.

How has CRSP stock performed over the past year?

CRISPR Therapeutics AG returned -11.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CRISPR Therapeutics AG do?

CRISPR Therapeutics AG is a Swiss biotechnology company focused on gene editing-based medicines for serious diseases. The company develops therapies using its proprietary CRISPR/Cas9 platform, which enables precise changes to DNA and supports a portfolio of programs across hemoglobin disorders, oncology, regenerative medicine, rare diseases, and autoimmune-related research areas.

What is the latest news on CRSP?

The most recent item we track (Zacks Investment Research, 3 Aug 2026): "CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates". CRISPR Therapeutics reported a Q2 loss of $0.94 per share, narrower than the Zacks Consensus Estimate of a $1.10 loss and an improvement from the $1.29 per share loss a year earlier. The company topped revenue estimates for the quarter.

Company

About CRISPR Therapeutics AG.

CRISPR Therapeutics AG is a Swiss biotechnology company focused on gene editing-based medicines for serious diseases. The company develops therapies using its proprietary CRISPR/Cas9 platform, which enables precise changes to DNA and supports a portfolio of programs across hemoglobin disorders, oncology, regenerative medicine, rare diseases, and autoimmune-related research areas. Its current product set includes approved and investigational cell and gene therapies designed to address conditions with significant unmet medical needs, while its research pipeline spans both ex vivo and in vivo approaches. CRISPR Therapeutics AG also works with strategic partners in biotech and life sciences to advance development and commercialization activities. Headquartered in Zug, Switzerland, the company plays a notable role in the evolving market for gene editing, where its technologies are used to create targeted, next-generation therapeutic candidates.

CEO Dr. Samarth Kulkarni Ph.D. · 393 employees · Switzerland · https://www.crisprtx.com